If you’re an income-focused investor looking for high yield with long-term stability, this newly added REIT may be exactly what you’ve been waiting for. Offering a forward dividend yield of 6.63%, this stock sits among the top 20% of all dividend-paying companies — and it’s backed by over 15 years of dividend increases. With a strategic focus on the life sciences real estate market, this REIT owns and operates mission-critical lab and R&D facilities in high-demand innovation hubs across North America. In a landscape where consistent income is becoming harder to find, this stock delivers both strong yield and institutional-grade portfolio quality.
The real estate it holds is at the heart of biotech and healthcare innovation — industries expected to grow as new drug approvals, gene therapies, and life sciences M&A continue to accelerate. While the macro environment presents some near-term challenges, including higher interest rates and cautious leasing activity, this REIT is actively managing through these risks with capital recycling and a disciplined focus on only the strongest markets. For long-term investors, the secular tailwinds remain firmly in place, and this stock is well-positioned to ride them with a mix of income and growth potential.
Curious how a life sciences REIT with a 6.6% yield is navigating today’s uncertain landscape — and why we’ve added it to our High Dividend Portfolio? Dive into the full article to uncover the data behind the buy signal, including dividend safety insights, sector trends, and what sets this stock apart from the crowd.
